Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11458390 | 0.77 | — | — | |
| SCHEMBL10575445 | 0.77 | CRBN (0.42) | CRBNCA2ALDH1A1NFKB1 | |
| SCHEMBL12435336 | 0.76 | CRBN (0.39) | CRBNTAS2R38KDM4ECA2PTGS1 | |
| SCHEMBL12512722 | 0.76 | CRBN (0.39) | CRBNTAS2R38KDM4ECA2PTGS1 | |
| SCHEMBL2220319 | 0.75 | — | — | |
| SCHEMBL10942414 | 0.75 | CRBN (0.43) | CRBNTAS2R38KDM4ECA2PTGS1 | |
| SCHEMBL6517566 | 0.72 | — | — | |
| SCHEMBL29616779 | 0.72 | DPP4 (0.48) | CRBNTAS2R38KDM4ECA2PTGS1 | |
| SCHEMBL25458289 | 0.70 | — | — | |
| SCHEMBL29616787 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007002173-A1 | HIV-1 PROTEASE INHIBITORS, AND METHODS OF MAKING AND USING THEM | UNIVERSITY OF MASSACHUSETTS (US) | 2007-01-04 | — | — | WO | disclosed |